Retatrutide 60mg

Description

Strength: 60mg
CAS: 2381089-83-2
Chemical Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular weight: 4845.444 g/mol
Peptide Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt)
Synonyms: Retatrutide acetate, LY3437943
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

Retatrutide (60 mg) is a triple-agonist synthetic peptide originally developed by Eli Lilly. It is designed to simultaneously activate GLP-1, GIP, and glucagon receptors, making it a compound of interest in advanced metabolic and cardiometabolic research.

Retatrutide (LY3437943) consists of a single 39-amino-acid peptide chain and incorporates fatty diacid acylation, a modification used to enhance albumin binding and prolong systemic exposure in research models.

The 60 mg vial size is intended to support extended, repeated, or high-volume laboratory protocols and does not represent a single human dosing level. No human clinical trial has evaluated doses exceeding 12 mg weekly.

This product is supplied as a lyophilized powder in sterile, sealed vials and is intended exclusively for laboratory research use.

• Triple-Receptor Activity: Concurrent GLP-1, GIP, and glucagon receptor agonism
• Long-Acting Profile: Approximate 6-day half-life observed in research settings
• High-Purity Lyophilized Form: Supports molecular stability and reproducibility
• Primary Research Focus: Obesity, insulin resistance, type 2 diabetes, and hepatic fat metabolism
• Clinical Context: Human trials evaluated once-weekly doses up to 12 mg only; the 60 mg vial format supports multi-week research protocols and is investigational and non-clinical
• Storage Stability: Requires controlled cold storage conditions
• Regulatory Status: Investigational compound; not FDA-approved
• Ordering Information: Qualified institutions may buy retratrutide peptide from authorized suppliers

Retatrutide exhibits a triple-agonist mechanism, enabling coordinated modulation of multiple metabolic pathways. This allows researchers to examine integrated effects on energy balance, glucose regulation, insulin dynamics, and lipid metabolism.

Key receptor-specific activities investigated in research include:

• GLP-1 signaling: Appetite regulation and improved glycemic control
• GIP signaling: Enhanced glucose-dependent insulin responsiveness
• Glucagon receptor activity: Increased energy expenditure and lipid utilization

The 60 mg format is particularly suited for extended in vitro studies, formulation research, and repeated-assay protocols requiring higher peptide quantities.

Published Phase 2 clinical trials evaluated retatrutide peptide at once-weekly doses up to 12 mg over 48 weeks, forming the current evidence base for its metabolic effects.

Phase 3 trials (TRIUMPH program) are evaluating 4 mg, 9 mg, and 12 mg once-weekly doses; no higher doses are under investigation.

Observed effects reported in existing research include:

• Significant body-weight reduction
• Improved glucose regulation and insulin sensitivity
• Reduced hepatic fat content
• Mild, transient increases in resting heart rate

All findings are derived from controlled clinical or preclinical research settings.

• Lyophilized Storage: Store at 2–8 °C, protected from light and moisture
• Long-Term Storage: Unopened vials may be stored at –20 °C to –80 °C
• After Reconstitution: Do not refreeze; follow protocol-specific stability guidance

Researchers who order retratrutide peptide in the 60 mg format must ensure full compliance with institutional review boards (IRBs), Institutional Animal Care and Use Committees (IACUCs) where applicable, and all federal and international research regulations.

References

https://pubmed.ncbi.nlm.nih.gov/37366315/

https://www.nature.com/articles/s41591-024-03018-2

https://pubmed.ncbi.nlm.nih.gov/37385280/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12304053/

https://pubmed.ncbi.nlm.nih.gov/40291085/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.